Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. drug maker is increasing its sales forces in emerging markets “very significantly”, even at a time when the company is reducing its sales force in U.S. and Europe.

You may also be interested in...

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

For Burgeoning Emerging Markets, All Business is Local

With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago

GSK Forms Joint Venture With Shenzhen Neptunus Interlong Bio-Technique For Flu Vaccine

HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts